Viewing Study NCT00717704


Ignite Creation Date: 2025-12-24 @ 9:09 PM
Ignite Modification Date: 2025-12-25 @ 7:00 PM
Study NCT ID: NCT00717704
Status: COMPLETED
Last Update Posted: 2020-08-05
First Post: 2008-07-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Solid Tumors Using Ixabepilone and Dasatinib
Sponsor: Medstar Health Research Institute
Organization:

Study Overview

Official Title: A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors
Status: COMPLETED
Status Verified Date: 2012-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients are being asked to take part in this study because they have been diagnosed with an advanced solid tumor that is not responding to standard treatments. This study will find the highest dose of ixabepilone and dasatinib in combination that can be given without causing severe side effects.

Both ixabepilone and dasatinib have individually been tested in many (several thousand) patients, however the combination of the two drugs has not yet been tested in humans.

All patients who will take part in this study will receive combined drug therapy of dasatinib and ixabepilone. Dasatinib is a pill that is taken by mouth. Ixabepilone is a medicine that will be given by vein (IV).

All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: